Posts tagged immunotherapy
Maxim downgrades Opexa Therapeutics to hold

Maxim Group downgraded Opexa Therapeutics (NASDAQ:OPXA) to “hold” from “buy” and removed its previous price target of $18 after the company failed a Phase 2b trial in secondary progressive multiple sclerosis (SPMS). The stock is changing hands at $1.02, down $2.37, in trading Friday afternoon.

Opexa’s T cell-based immunotherapy, Tcelna, did not meet the primary endpoint of brain atrophy and the secondary endpoint of reduced rate of disease progression also was not met

Read More
HCW downgrades Agenus to neutral

H.C. Wainwright downgraded Agenus (NASDAQ:AGEN) to “neutral” from “buy” and slashed its price target to $5 from $10. The stock closed at $4.33 on Thursday.

Analyst Swayampakula Ramakanth writes that during Agenus’ third quarter earnings, the company announced development of CTLA-4 and PD-1 checkpoint modulators (CPMs) as the focus of the company’s cancer immunotherapy pipeline.

Read More
Maxim cuts Galena Biopharma price target to $1

Maxim Group lowered its price target for Galena Biopharma (NASDAQ:GALE) to $1 from $2, citing a shift in the company’s pipeline focus. The stock closed at 46 cents on Tuesday.

At the end of June, an Independent Data Monitoring Committee stopped a Phase 3 trial of Galena’s NeuVax in early-stage breast cancer for futility.

Read More